1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Streptococcus pyogenes Infections - Pipeline Review, H1 2017

Streptococcus pyogenes Infections - Pipeline Review, H1 2017

  • February 2017
  • -
  • Global Markets Direct
  • -
  • 42 pages

Streptococcus pyogenes Infections - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Streptococcus pyogenes Infections – Pipeline Review, H1 2017, provides an overview of the Streptococcus pyogenes Infections (Infectious Disease) pipeline landscape.

Streptococcus pyogenes infections are caused by Streptococcus pyogenes, a spherical, Gram-positive bacterium. Symptoms include significant pain, swelling, and redness of infected area, fever, dizziness, difficulty breathing, dangerously low blood pressure, and a weak, rapid pulse. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Streptococcus pyogenes Infections – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Streptococcus pyogenes Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Streptococcus pyogenes Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Streptococcus pyogenes Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 6 and 4 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Streptococcus pyogenes Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Streptococcus pyogenes Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Streptococcus pyogenes Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Streptococcus pyogenes Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Streptococcus pyogenes Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Streptococcus pyogenes Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Streptococcus pyogenes Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table Of Contents

Streptococcus pyogenes Infections - Pipeline Review, H1 2017
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Streptococcus pyogenes Infections - Overview
Streptococcus pyogenes Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Streptococcus pyogenes Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Streptococcus pyogenes Infections - Companies Involved in Therapeutics Development
Absynth Biologics Ltd
Antibiotx ApS
AstraZeneca Plc
Crestone Inc
Emergent BioSolutions Inc
Griffith University
Helix BioMedix Inc
Sumitomo Dainippon Pharma Co Ltd
Wellstat Vaccines LLC
Streptococcus pyogenes Infections - Drug Profiles
AZ-6142 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
EV-035 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
HB-1345 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
niclosamide - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SM-295291 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
SM-369926 - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Small Molecules to Inhibit PolC for Gram-Positive Bacterial Infections - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Streptococcus [serotype A] vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Streptococcus pyogenes (30-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Streptococcus pyogenes vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Streptococcus pyogenes vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Streptococcus pyogenes vaccine - Drug Profile
Product Description
Mechanism Of Action
RandD Progress
Streptococcus pyogenes Infections - Dormant Projects
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Streptococcus pyogenes Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Streptococcus pyogenes Infections - Pipeline by Absynth Biologics Ltd, H1 2017
Streptococcus pyogenes Infections - Pipeline by Antibiotx ApS, H1 2017
Streptococcus pyogenes Infections - Pipeline by AstraZeneca Plc, H1 2017
Streptococcus pyogenes Infections - Pipeline by Crestone Inc, H1 2017
Streptococcus pyogenes Infections - Pipeline by Emergent BioSolutions Inc, H1 2017
Streptococcus pyogenes Infections - Pipeline by Griffith University, H1 2017
Streptococcus pyogenes Infections - Pipeline by Helix BioMedix Inc, H1 2017
Streptococcus pyogenes Infections - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017
Streptococcus pyogenes Infections - Pipeline by Wellstat Vaccines LLC, H1 2017
Streptococcus pyogenes Infections - Dormant Projects, H1 2017

List of Figures
Number of Products under Development for Streptococcus pyogenes Infections, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • November 2016
  • by Global Markets Direct

DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘DNA Gyrase Subunit B (EC 5.99.1.3) - Pipeline Review, H2 2016’, provides in depth analysis on DNA Gyrase ...

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2016

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide ...

Burkholderia Infections - Pipeline Review, H2 2016

Burkholderia Infections - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • December 2016
  • by Global Markets Direct

Burkholderia Infections - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Burkholderia Infections – Pipeline Review, H2 2016, provides ...

Q Fever - Pipeline Review, H2 2016

November 2016 $ 2000

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.